better informed clinical decisions to enhance patient outcomes
PROGNOSTICS THAT DEFINE CANCER PROGRESSION
LIVE IMAGING YOUR CANCER CELLS SO YOU KNOW WHAT THEY ARE DOING
GREATER SPECIFICITY AND SENSITIVITY IN DIAGNOSIS
Providing Therapeutic Targets for Multiple Cancers Using Unique Biomarkers
CREATING THE FUTURE STANDARD IN CANCER DIAGNOSIS, PROGNOSIS, LIVE CELL IMAGING AND PROVIDING THERAPEUTIC TARGETS
Envision Sciences is a cell biology company with a primary focus on diagnostics, prognostics, live cell imaging and identification of targets for therapeutic treatments. Our goal is to lead the way in providing high specificity and sensitivity outcomes across various forms of cancer.
The products we are developing are designed to provide much clearer advice on the status of cancer in pathology samples from the human body. We aim to provide solutions for clinicians, giving more detailed information on the level and activity of a cancer and allowing them to make much more specific diagnosis and improved treatment decisions for their patients across a complete diagnosis and prognosis spectrum.
Our ’ Vision’ is to position Envision Sciences as a leading oncology diagnostic, prognostic and companion diagnostic company. Our novel biomarker discovery program will also define new targets for specific therapeutic intervention in cancer patients.
Envision’s primary ‘Goals’ are:
- to provide new industry standards in diagnostics, prognostics and companion diagnostics for a range of cancers, enabling healthcare service providers to achieve better patient outcomes
- to provide game changing diagnostics, prognostics and companion diagnostics for cancers with unmet needs; specifically those with very poor prognosis and often referred to in lay terms as the ‘killer’ cancers
Envision’s approach for interaction with diagnostic and therapeutic provider companies:
- early engagement with stakeholders to develop innovative collaboration models for patient access to our technology, and to create win-win business solutions for our partners
- the provision of viable therapeutic targets for multiple cancers and to co-operatively develop novel strategies for effective cancer treatment and patient management
Envision’s ‘novelty’ is built on technology that is based around a very solid foundation.
- The core of the technology is based on unique, confirmed, cell biology pathways, which define the primary pathogenesis and enable the development of tests that are objective, verifiable and quantifiable
Envision’s novel biomarkers:
- provide a full spectrum cancer pathology solution for early diagnosis, accurate prognosis and companion diagnosis
- provide unique solutions for precision disease mapping and the definition of disease phenotype
- provide precision medicine to drive selective evidence based therapeutic options for patients rather than using subjective estimates of disease biology
- provide high affinity reagents that depict specific pathology and allow digital pathology solutions to remove subjective error
- are the first to identify aggressive migrating cancer cells and can visualize the first signs of aggressive cancer
- have direct links to imaging and therapeutic technologies by identifying critical targets in cancer pathogenesis
Envision Sciences was formed in 2017 and is based in Adelaide in South Australia. Its foundation is based on high potential cancer research outcomes in cell biology that had their genesis in the University of South Australia.
Board / Leadership Team
PETER PURSEY AM
Executive Chairman / Chief Executive Officer
Peter has led a range of teams in his career and is an experienced leader and strategic planner. He has led the development and strategic direction of the therapeutics company PresSura Neuro for over 5 years and brings all the experience of development, clinical trials and an expertise in international industry networks to Envision. He is experienced at capital raising across a number of industries in Australia and overseas, and his skill sets are well suited to lead the development and commercial goals set for Envision.
Peter is an experienced public company executive and has held director positions in various companies and industry sectors including in energy, mining services and medical therapeutics. His recent appointments include being chairman of PresSura Neuro (therapeutics for traumatic brain injury and concussion), executive chairman of Austin Engineering (ASX Code:ANG) in 2016.
PROFESSOR DOUG BROOKS
Chief Scientific Officer/ Executive Director
Doug is the leader of the Mechanisms in Cell Biology and Disease Research Group at the University of South Australia Cancer Research Institute.
Professor Brooks current focus for Envision Sciences is on biomarker development for prostate and a number of other cancers, including work on biomarkers for tissue histology, the early detection of cancer and companion diagnostics. Doug has over 30 years experience in medical research and is also a Research Professor in Molecular Medicine. His initial research training was in Immunology with a focus on cancer research, involving the immunochemistry of cell surface antigens
JOHN HIGGINS AO
Non Executive Director
John is an experienced businessman with extensive experience in the international business environment. He holds chair and director appointments across a number of business industry sectors in Australia and overseas.
Dr PIERRE VANKAN
Pierre has extensive pharmaceutical experience, having worked for Hoffman LaRoche as a team leader and also with Santhera Pharmaceuticals in Switzerland. He is very experienced in all pharmaceutical developments from preclinical through to and beyond Phase 2 human trials. He has also led product to market teams and has a very extensive commercial industry network globally.
He has a PhD majoring in molecular biology.
Diagnostic Development and Commercialisation – Lead
Seong brings to Envision 16 years experience in diagnostics including roles in major global diagnostic companies. He specilaises in the development of diagnostic technology, business development and commercialisation. He has also worked for the Boston Consulting Group and his skills include business analysis, molecular diagnostics, commercial solutions and global business development including solutions for personalised medicine. Seong has a B Eng (Hons) from Melbourne University and an MBA from Berkeley.
Science and Technology
Envision Sciences is developing a range of diagnostic, prognostic and live cell imaging products based on cutting edge cell biology research and discovery. Our current technology development covers the following areas:
There is a need for cancer diagnostics that provide a much greater level of sensitivity, specificity and validity than exist in the
marketplace at the moment. The development of our products in this field has an initial focus on specific cancer and we expect to expand the outcomes of our work into a broader range of cancers.
While there are numerous tests to indicate the presence of a cancer there are limited non-invasive tests that identify whether the cancer is passive or aggressive. Clinicians need specific information on which to base treatment options and advice to their patients. Our prognostic developments are designed to provide a much higher level of information to clinicians. The prognostic tests being developed are also focused to markedly improve the current lack of information from existing cancer “prognostic” tests.
Live Cell ImagingOur work in this area provides for live monitoring of cancer cells from biopsy tissue. This ground breaking work is also designed to give clinicians very precise information on a patients specific cancer and its level of activity. This will allow clinicians to provide very accurate diagnosis using live, visual diagnostic tools as well as prognosis advice on when and what level of surgery or other treatment is required for their patients.
Therapeutics (biologics) and Companion Diagnostics
Our ground breaking work on biological pathways has led to the development of unique biomarkers for diagnosis and prognosis. This has allowed us to identify targets for therapeutic intervention in multiple cancers. This work also includes the development of PET imaging agents to visualise cancer in patients.
Envision works with numerous high end partners and affiliates who are leaders in their field.
Some of our key PARTNERS and COLLABORATORS include:
If you would like to ask a question or have a general enquiry please contact us by completing the form below.